NKR-2 cells

BIOLOGICAL3 trials

Sponsors

Celyad Oncology SA

Conditions

Acute Myeloid Leukemia/Myelodysplastic SyndromeColon Cancer Liver MetastasisMultiple Myeloma (MM)

Phase 1

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

Celyad Oncology SAAcute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)

Start: 2016-12-31End: 2021-08-31Target: 146Updated: 2019-09-19

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases

Celyad Oncology SAColon Cancer Liver Metastasis

Start: 2017-08-07End: 2021-05-31Target: 36Updated: 2020-06-16

Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

TerminatedNCT03370198

Celyad Oncology SAColon Cancer Liver Metastasis

Start: 2017-10-11End: 2018-12-15Updated: 2024-02-28

Related Papers

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.

2023-02-0774 citations

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood2020-11-048 citations

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood2019-11-1324 citations

PS1212 UPDATED RESULTS FROM PHASE I TRIALS ASSESSING A NKG2D CAR T‐CELL APPROACH IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME PATIENTS

HemaSphere2019-06-01

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

Blood2018-11-2925 citations

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Blood2018-11-292 citations

Tackling fratricide to manufacture clinical grade NKG2D-CAR T cells for cancer therapy

Annals of Oncology2018-10-011 citations

Abstract CT129: The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia

Cancer Research2018-07-017 citations

Abstract CT134: A phase I study assessing the safety and clinical activity of multiple hepatic transarterial administrations of a NKG2D-based CAR-T therapy CYAD-01, in patients with unresectable liver metastases from colorectal cancer

Cancer Research2018-07-014 citations

Abstract CT123: A phase I study assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer

Cancer Research2018-07-012 citations

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

BMJ Open2017-11-0148 citations

A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types.

Journal of Clinical Oncology2017-05-204 citations